Completed PHASE4 INTERVENTIONAL 2-arm NCT02247414

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection (ESWAPH)

Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension

Sponsor: Yangzhou University

Conditions Cirrhosis Hypertension Status;Splenectomy Venous Thrombosis

Interventions Aspirin Dipyridamole Low Molecular Weight Heparin Warfarin

Updated 9 times since 2017 Last updated: Mar 28, 2019 Started: Sep 30, 2014 Primary completion: Sep 30, 2017 Completion: Apr 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cirrhosis and Hypertension and is currently completed. Yangzhou University leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Apr 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Apr 2019 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed
May 2017 — Oct 2017 [monthly]

Recruiting PHASE4
Feb 2017 — May 2017 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yangzhou University

Data source: Yangzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yangzhou, China